IRVING, Texas, June 16 /PRNewswire-FirstCall/ -- RBC Life Sciences: (OTC Bulletin Board: RBCL) -- RBC Life Sciences, Inc., a provider of proprietary nutritional supplements and wound care/pain management products, announced today that all seven members of the board of directors were re-elected during the company's 2009 shareholders meeting.
RBC Life Sciences CEO and President John W. Price opened the meeting recapping the factors that led to the 13 percent growth in net sales during 2008 and the company's prospects for continued growth throughout 2009. Despite the slow economy, an estimated 2,500 new independent Associates have joined RBC Life Sciences during the last seven months -- more than a 25 percent increase in the number of Associates the company had when it launched efforts to build its North American sales base in November 2008.
Re-elected to the board of directors in the meeting were: Clinton H. Howard, outside director and chairman of the board; Mr. Price; Steven E. Brown, chief financial officer and vice president of finance; Kenneth L. Sabot, senior vice president of operations; Paul Miller, president of MPM Medical, Inc.; Joseph P. Phillip, independent director; and Robert A. Kaiser, independent director.
About RBC Life SciencesRBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical brand, RBC Life Sciences also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than 30 countries in which the products are distributed. For more information, visit the Company's Web site at www.rbclifesciences.com.
The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange
|SOURCE RBC Life Sciences, Inc.|
Copyright©2009 PR Newswire.
All rights reserved